drugset / Trial / NCT06625398
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).
Timeline
- Start
- 2024-08-27
- Primary completion
- 2026-03-04
- Completion
- 2026-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VRDN-003 | Monoclonal antibody | — | Subcutaneous |